Contract Option Exercises — May 21, 2026

Leidos Holdings subsidiary secured a $432.5 million cost-plus-fixed-fee delivery order from NIH to operate a government-owned R&D facility through May 2026. This provides a predictable ~$64.6 million annual revenue stream with low pricing risk, though only $1.15 million has been outlayed so far, indicating early-stage execution.

Peraton Inc. secured a $95.1 million time-and-materials delivery order from CMS for the Fraud Prevention System 2, with options up to $118.7 million. This is a high-priority, politically supported area with ~$23.8 million annual revenue potential, though time-and-materials pricing introduces medium cost risk.

SOFTRAMS LLC's firm-fixed-price HUBZone set-aside contract with CMS ends August 3, 2024, with no options. With $52.5 million already outlayed (65% execution), the company faces a potential revenue cliff if the contract is not renewed or recompeted, given the fixed-price cost risk and upcoming expiration.

General Dynamics Information Technology won a $1.25 billion ceiling cost-plus-award-fee delivery order from GSA for enterprise IT management support, with an initial $70.6 million obligation through early 2027 and options to 2033. This provides a long-term revenue stream (~$168-209M/year) but with capped profit upside due to cost-plus pricing.

Chimerix, Inc.'s 2011 BARDA contract for biotechnology R&D, valued at $77.1 million, expired in 2021 with only $52,775 outlayed. This historical award signals past government confidence but has negligible current financial impact, with no new BARDA contracts identified in this digest.

HHS accounts for 90.7% of total obligation value ($685.3M of $755.9M), creating extreme agency concentration risk. Any HHS budget cuts or continuing resolution impacts would disproportionately affect the portfolio.

Leidos' $432.5M NIH contract has only $1.15 million outlayed (0.3% execution), indicating early-stage or slow ramp-up. Delays in facility operations or scope changes could affect revenue recognition and margin expectations.

SOFTRAMS LLC's $80.7M CMS contract expires August 2024 with no options. As a HUBZone set-aside, recompetition may attract other small businesses, and the fixed-price structure could pressure margins if labor costs rise.

Peraton's $95.1M CMS Fraud Prevention System 2 contract is time-and-materials, meaning CMS bears cost risk but Peraton faces funding uncertainty if CMS fraud prevention budgets are cut or reprioritized.

GDIT's $1.25B EMITS 2 contract with GSA provides a long-term (2025-2033) enterprise IT management revenue stream. Option exercises could increase the current $70.6M obligation significantly, with annual revenue potential of $168-209M.

SOFTRAMS LLC's HUBZone set-aside contract with CMS, despite its 2024 expiration, signals policy alignment that could lead to follow-on awards. The company's 65% execution rate suggests strong performance, positioning it for recompetition or new CMS contracts.

Peraton's CMS Fraud Prevention System 2 contract has options up to $118.7 million, offering ~25% upside from the current $95.1M obligation. Continued political support for healthcare fraud prevention could drive option exercises.

Two of the five contracts (Peraton's $95.1M CMS FPS2 and GDIT's $1.25B GSA EMITS 2) are focused on IT systems and fraud prevention, totaling $165.7M in obligations. This reflects sustained civilian agency investment in digital modernization and program integrity, despite broader budget uncertainty.

Leidos' $432.5M NIH GOCO contract and Chimerix's historical $77.1M BARDA award highlight government investment in life sciences R&D infrastructure. However, cost-plus pricing limits profit upside, making these contracts more about revenue stability than margin expansion.

{"entity"=>"SOFTRAMS LLC", "reason"=>"Upcoming August 2024 contract expiration creates a potential revenue cliff; recompetition status is critical.", "trigger"=>"CMS recompetition announcement or contract extension before August 3, 2024"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"Only 0.3% of $432.5M NIH contract outlayed; execution pace will determine revenue recognition trajectory.", "trigger"=>"Quarterly outlay rates and NIH contract modifications through May 2026"}

{"entity"=>"Peraton Inc.", "reason"=>"CMS Fraud Prevention System 2 option exercises could add up to $23.7M in additional revenue.", "trigger"=>"Option exercise announcements by June 2027"}

{"entity"=>"General Dynamics Corporation", "reason"=>"EMITS 2 contract has $1.25B ceiling but only $70.6M obligated; option exercises will signal long-term revenue potential.", "trigger"=>"GSA option exercise announcements and incremental funding obligations through 2033"}